DIEPPE, New Brunswick, March 04, 2025 (GLOBE NEWSWIRE) — Hexiris Inc. (“Hexiris” or the “Company“), a leading R&D medtech company dedicated to developing innovative, accessible, and effective ophthalmic solutions for patients and community ophthalmologists, is pleased to announce the appointment of Paul Sowyrda and Steven Schiffman to its Board of Directors.
Hexiris Welcomes Paul Sowyrda and Steven Schiffman to Its Board of Directors
Strategic Growth for Hexiris
“We are thrilled to welcome Paul Sowyrda and Steven Schiffman to our Board. Their extensive industry knowledge and proven expertise in strategic foresight, investment strategy, and corporate leadership will play a pivotal role in driving Hexiris’ growth and advancing its mission to address critical unmet needs in ophthalmology worldwide,” said Houfar Sekhavat, Co-Founder, Chairman and Co-CEO of Hexiris.
Paul Sowyrda:
A Visionary in Biopharmaceutical and Medical Device Development
With over 25 years of experience in the life sciences industry, Paul Sowyrda has demonstrated leadership across every phase of development. He currently serves on the Board of Directors at Alloplex Biotherapeutics and the Society of Concurrent Product Development. As co-founder of Novellus, Inc., he played a …
